The Pharmacokinetics study of Imeglimin (PXL008) in Japanese Subjects with Renal Impairment
Latest Information Update: 07 Mar 2023
At a glance
- Drugs Imeglimin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Poxel; Sumitomo Dainippon Pharma
- 27 Feb 2023 Results published in the Journal of Clinical Pharmacology.
- 21 Dec 2021 New trial record